Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Intercept's Ocaliva Seems Headed For Black Box On Liver Injury Risk

Sep 25 2017

• By Joseph Haas

Emptyblisterpack_1200x675

Related Content

Intercept Seeks Long-Term Data To Build <em>Ocaliva</em> Market In PBC

Nov 16 2016

'Clean Label' For Intercept's Ocaliva In PBC Bodes Well For NASH Claim

Jun 06 2016

Intercept's Revised NASH Trial Improves Prospects

Feb 13 2017

Related Companies

Intercept Pharmaceuticals, Inc.

Additional Topics

Risk Management Drug Safety Clinical Trials FDA Liver & Hepatic BioPharmaceutical

More from Drug Safety

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window